Proteolysis Targeting Chimera (PROTAC) technology has emerged over the last two decades as a powerful tool for targeted degradation of proteins. This presentation will detail the development of PROTACs for the degradation of both the receptor tyrosine kinase FLT-3 and the oncogenic fusion protein BCR-ABL. Not only does this provide evidence for the use of PROTACs as potential therapeutics for both Acute and Chronic Myeloid Leukemia but also provided tools to elucidate the kinase independent roles of these proteins. In both cases, we identified differential biology between inhibition and degradation in a variety of systems including patient stem cells and murine xenografts.

Targeted protein degradation as a tool to probe non-kinase roles in myeloid leukemias

2019 Fall National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.